ClinicalTrials.gg
CompletedNCT01348490Updated Jan 28, 2020Results posted

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

A Phase 2 interventional study of Ruxolitinib in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing ruxolitinib in Myeloproliferative Disorders — 2 open to participants now, 4 under way, none of them phase 3. ruxolitinib · Myeloproliferative Disorders.

Enrollment
7th of 19
66 · median 49
Started
2011
with 1 other
Phase 2
7 of 19
1 open now
Registered
5th of 19
by date
Lead sponsor
5 of 19
Incyte Corporation

Among the 19 studies testing ruxolitinib in Myeloproliferative Disorders, this one is the 7th largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 2, and was the 5th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

2 of the 19 studies testing ruxolitinib in Myeloproliferative Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing ruxolitinib in Myeloproliferative Disorders, or all of them as a file.
02

Study summary

To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10\^9/L to 100 x 10\^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.

03

Conditions studied

  • MPN (Myeloproliferative Neoplasms)

Keywords

  • PMF
  • PPV-MF
  • PET-MF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow
  • Discontinuation of all drugs used to treat underlying MF disease at least 14 days prior to baseline visit
  • \<= 1.5 or PTT value \< 1.5 x (ULN) at study entry
  • level at least 6.5 g/dL at Screening visit
  • Willingness to be transfused to treat low hemoglobin levels

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, unable to comply with use to avoid becoming pregnant or breastfeeding
  • Males who cannot comply with birth control use to avoid fathering a child
  • count \< 50 x10\^9/L or (ANC) \< 1 x10\^9/L at the Screening visit
  • Inadequate liver or renal function; Intracranial bleeds or invasive over the previous 2 years - (INR) laboratory values cannot be > 1.5 x at study entry.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Ruxolitinib 5 mg

    Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.

    Drug: Ruxolitinib

Interventions

  • Ruxolitinib (INCB018424), 5 mg bid

    Also known as: INCB018424

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose

    Magnetic resonance imaging (MRI) of the upper and lower abdomen and pelvis was performed to assess spleen volumes. Computed tomography (CT) scan was performed if participant was not a candidate for MRI or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

    Time frame: Baseline and Week 24

  2. Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose

    Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.

    Time frame: Baseline and Week 24

  3. Percentage of Participants With Treatment-emergent Adverse Events (TEAE)

    TEAE was defined as adverse events that began or worsened from baseline after the first administration of the study drug. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.

    Time frame: Up to Week 156

  4. Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)

    Participants with platelet count between 50 and 100 × 10\^9/L at the screening and/or baseline visit were enrolled in the study. Thrombocytopenia is defined as a condition with low blood platelet count. Grade 4 thrombocytopenia was platelet count \< 25 × 10\^9/L. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.

    Time frame: Up to Week 156

  5. Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03

    Hemorrhages were defined as any lower level terms by MedDRA included in the Standardized MedDRA Query (SMQ) for hemorrhage terms. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.

    Time frame: Up to Week 156

Secondary outcomes

  1. Percent Change in Spleen Volume at Week 24 Compared to Baseline

    MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant was not a candidate for MRI, or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

    Time frame: Baseline and Week 24

  2. Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline

    Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms..

    Time frame: Baseline and Week 24

  3. Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline

    MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

    Time frame: Baseline and Week 24

  4. Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline

    MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

    Time frame: Baseline and Week 24

  5. Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline

    Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.

    Time frame: Baseline and Week 24

  6. Change in Spleen Length Measured by Palpation

    Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

    Time frame: Up to Week 156

  7. Percent Change From Baseline in Spleen Length Measured by Palpation

    Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

    Time frame: Up to Week 156

  8. Patient Global Impression of Change (PGIC) Score at Each Visit

    Symptoms of myelofibrosis were assessed using the PGIC questionnaire. Using the questionnaire, patients rated the overall sense of treatment effect on their symptoms on a scale of 1 (very much improved)- 7(very much worse). The specific wording was: Since the start of the treatment you've received in this study, your myelofibrosis symptoms are: 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse. A higher score indicates worse symptoms.

    Time frame: Up to Week 156

07

Results

Posted Jan 28, 2020
Limitations and caveats
Participants with platelet counts of 50 to 100 x 10\^9/L were enrolled to begin ruxolitinib at 5 mg BID. Subjects could then titrate their dose to an dose that offers benefit. Only the overall data was calculated for the Participant and Baseline data.

Participant flow

Participants took part in the study at 27 investigative sites in the United States from 15 June 2011 to 19 December 2018.

Participant flow — Overall Study
MilestoneRuxolitinib 5 Milligram (mg)
Started66
Completed42
Not completed24
Withdrew: Death1
Withdrew: Adverse event3
Withdrew: Consent withdrawn7
Withdrew: Disease progression3
Withdrew: Lost to follow-up1
Withdrew: Termination of clinical trial by sponsor1
Withdrew: Other unspecified8

Outcome measures

PrimaryPercent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose

Magnetic resonance imaging (MRI) of the upper and lower abdomen and pelvis was performed to assess spleen volumes. Computed tomography (CT) scan was performed if participant was not a candidate for MRI or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percentage change from baseline
Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose
Percentage change from baseline5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose-11.6 ± 18.68-17.4 ± 0.63-22.4 ± 22.86-13.4 ± 22.29
Statistical analysis
  • 5 mg QD or 5 mg BID · t-test, 1 sided · p = 0.0250 (1-sample t-test was used.)
  • 5 mg AM/ 10 mg PM · t-test, 1 sided · p = 0.0163 (1-sample t-test was used.)
  • 10 mg BID · t-test, 1 sided · p = <0.0001 (1-sample t-test was used.)
  • 10 mg AM/ 15 mg PM or 15 mg BID · t-test, 1 sided · p = 0.2019 (1-sample t-test was used.)
PrimaryPercent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose

Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percentage change from baseline
Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose
Percentage change from baseline5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose-6.35 ± 64.207-39.51 ± NA-47.54 ± 46.8867.95 ± 113.17
Statistical analysis
  • 5 mg QD or 5 mg BID · t-test, 1 sided · p = 0.6887 (1-sample t-test was used.)
  • 10 mg BID · t-test, 1 sided · p = <0.0001 (1-sample t-test was used.)
  • 10 mg AM/ 15 mg PM or 15 mg BID · t-test, 1 sided · p = 0.8701 (1-sample t-test was used.)
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAE)

TEAE was defined as adverse events that began or worsened from baseline after the first administration of the study drug. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.

Time frame:
Up to Week 156
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAE)
percentage of participants>0 - 5 mg>5 - 10 mg>10 - 15 mg>15 - 20 mg>20 mg
Percentage of Participants With Treatment-emergent Adverse Events (TEAE)93.374.261.177.355.6
PrimaryPercentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)

Participants with platelet count between 50 and 100 × 10\^9/L at the screening and/or baseline visit were enrolled in the study. Thrombocytopenia is defined as a condition with low blood platelet count. Grade 4 thrombocytopenia was platelet count \< 25 × 10\^9/L. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.

Time frame:
Up to Week 156
Reported as:
Number · percentage of participants
Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)
percentage of participants>0 - 5 mg>5 - 10 mg>10 - 15 mg>15 - 20 mg>20 mg
Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)23.13.05.74.70.0
PrimaryPercentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03

Hemorrhages were defined as any lower level terms by MedDRA included in the Standardized MedDRA Query (SMQ) for hemorrhage terms. Participants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.

Time frame:
Up to Week 156
Reported as:
Number · percentage of participants
Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03
percentage of participants>0 - 5 mg>5 - 10 mg>10 - 15 mg>15 - 20 mg>20 mg
Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.036.73.01.92.311.1
SecondaryPercent Change in Spleen Volume at Week 24 Compared to Baseline

MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant was not a candidate for MRI, or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percentage
Percent Change in Spleen Volume at Week 24 Compared to Baseline
PercentageRuxolitinib
Percent Change in Spleen Volume at Week 24 Compared to Baseline-17.8 ± 21.27
Statistical analysis
  • Ruxolitinib · t-test, 1 sided · p = <0.0001 (1-sample t-test was used.)
SecondaryPercent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline

Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms..

Time frame:
Baseline and Week 24
Reported as:
Mean · Percentage change from baseline
Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline
Percentage change from baselineRuxolitinib
Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline-27.90 ± 64.818
Statistical analysis
  • Ruxolitinib · t-test, 1 sided · p = 0.0028 (1-sample t-test was used.)
SecondaryPercentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline

MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline
percentage of participants5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline4.8 (0.1 to 23.8)0.0 (0.0 to 70.8)24.2 (11.1 to 42.3)28.6 (3.7 to 71.0)
SecondaryPercentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline

MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline
percentage of participants5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline42.9 (21.8 to 66.0)66.7 (9.4 to 99.2)63.6 (45.1 to 79.6)28.6 (3.7 to 71.0)
SecondaryPercentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline

Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline
percentage of participants5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline28.6 (11.3 to 52.2)0.0 (0.0 to 70.8)44.1 (27.2 to 62.1)28.6 (3.7 to 71.0)
SecondaryChange in Spleen Length Measured by Palpation

Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

Time frame:
Up to Week 156
Reported as:
Mean · cm
Change in Spleen Length Measured by Palpation
cm5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Baseline11.48 ± 5.81014.00 ± 4.35913.13 ± 8.24114.71 ± 6.726
Change at Week 4-3.40 ± 3.068-4.00 ± 6.083-1.84 ± 3.1950.00 ± 3.688
Change at Week 8-4.65 ± 3.558-5.33 ± 4.933-2.81 ± 3.514-1.14 ± 2.340
Change at Week 12-4.53 ± 4.812-6.50 ± 3.536-3.74 ± 5.118-3.71 ± 7.544
Change at Week 16-3.79 ± 4.973-4.50 ± 3.536-3.69 ± 4.343-2.00 ± 2.449
Change at Week 20-4.56 ± 4.844-7.50 ± 4.950-5.28 ± 5.567-3.50 ± 7.064
Change at Week 24-4.25 ± 5.092-7.00 ± 5.657-4.57 ± 5.541-1.33 ± 3.983
Change at Week 36-7.00 ± NA-11.00 ± NA-2.75 ± 3.8621.00 ± NA
Change at Week 48-7.00 ± NA-11.00 ± NA-2.33 ± 2.5170.00 ± 0.000
Change at Week 60-7.00 ± NA-11.00 ± NA-2.67 ± 2.5171.50 ± 2.121
Change at Week 72-4.00 ± NA-11.00 ± NA-1.50 ± 2.1211.00 ± NA
Change at Week 84-4.00 ± NA—-3.00 ± NA-2.00 ± NA
Change at Week 96-4.00 ± NA-8.00 ± NA0.00 ± NA—
Change at Week 108-4.00 ± NA-10.00 ± NA0.00 ± NA—
Change at Week 120-4.00 ± NA-6.00 ± NA2.00 ± NA—
Change at Week 132-4.00 ± NA-5.00 ± NA1.00 ± NA—
Change at Week 144-4.00 ± NA-3.00 ± NA0.00 ± NA—
Change at Week 156-4.00 ± NA-3.00 ± NA0.00 ± NA—
SecondaryPercent Change From Baseline in Spleen Length Measured by Palpation

Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.

Time frame:
Up to Week 156
Reported as:
Mean · Percentage
Percent Change From Baseline in Spleen Length Measured by Palpation
Percentage5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Percent Change at Week 4-38.61 ± 36.532-26.62 ± 36.906-21.88 ± 33.800-1.42 ± 22.902
Percent Change at Week 8-50.64 ± 39.930-37.95 ± 28.772-28.32 ± 31.151-8.72 ± 13.991
Percent Change at Week 12-49.90 ± 48.623-50.35 ± 8.348-38.21 ± 39.936-22.41 ± 40.833
Percent Change at Week 16-43.24 ± 48.173-32.99 ± 15.222-38.67 ± 36.070-14.33 ± 14.903
Percent Change at Week 20-44.58 ± 46.490-56.60 ± 17.187-48.06 ± 38.826-27.75 ± 39.024
Percent Change at Week 24-45.39 ± 53.913-51.04 ± 25.043-42.01 ± 36.899-9.89 ± 25.001
Percent Change at Week 36-58.33 ± NA-68.75 ± NA-20.76 ± 27.6375.00 ± NA
Percent Change at Week 48-58.33 ± NA-68.75 ± NA-31.82 ± 19.2850.00 ± NA
Percent Change at Week 60-58.33 ± NA-68.75 ± NA-36.36 ± 12.85615.00 ± NA
Percent Change at Week 72-33.33 ± NA-68.75 ± NA-27.27 ± NA5.00 ± NA
Percent Change at Week 84-33.33 ± NA—-27.27 ± NA-10.00 ± NA
Percent Change at Week 96-33.33 ± NA-50.00 ± NA——
Percent Change at Week 108-33.33 ± NA-62.50 ± NA——
Percent Change at Week 120-33.33 ± NA-37.50 ± NA——
Percent Change at Week 132-33.33 ± NA-31.25 ± NA——
Percent Change at Week 144-33.33 ± NA-18.75 ± NA——
Percent Change at Week 156-33.33 ± NA-18.75 ± NA——
SecondaryPatient Global Impression of Change (PGIC) Score at Each Visit

Symptoms of myelofibrosis were assessed using the PGIC questionnaire. Using the questionnaire, patients rated the overall sense of treatment effect on their symptoms on a scale of 1 (very much improved)- 7(very much worse). The specific wording was: Since the start of the treatment you've received in this study, your myelofibrosis symptoms are: 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse. A higher score indicates worse symptoms.

Time frame:
Up to Week 156
Reported as:
Mean · score on a scale
Patient Global Impression of Change (PGIC) Score at Each Visit
score on a scale5 mg QD or 5 mg BID5 mg AM/ 10 mg PM10 mg BID10 mg AM/ 15 mg PM or 15 mg BID
Week 42.8 ± 0.892.8 ± 1.262.6 ± 1.093.3 ± 0.76
Week 82.7 ± 1.222.3 ± 0.962.2 ± 0.992.9 ± 0.69
Week 122.4 ± 0.962.3 ± 1.152.2 ± 1.173.4 ± 1.27
Week 162.4 ± 0.832.0 ± 1.001.9 ± 0.913.3 ± 0.95
Week 202.4 ± 0.862.3 ± 0.581.9 ± 1.112.3 ± 0.82
Week 242.9 ± 1.272.3 ± 0.581.9 ± 0.982.0 ± 1.00
Week 362.0 ± NA3.0 ± NA1.8 ± 0.502.5 ± 0.71
Week 48—2.5 ± 0.711.3 ± 0.582.0 ± 0.00
Week 602.0 ± NA2.5 ± 0.711.7 ± 0.583.0 ± 0.00
Week 722.0 ± NA2.5 ± 0.71—4.0 ± NA
Week 84—2.0 ± NA1.0 ± 0.003.0 ± NA
Week 962.0 ± NA2.5 ± 0.71——
Week 1082.0 ± NA2.5 ± 0.711.0 ± NA—
Week 1202.0 ± NA2.5 ± 0.71——
Week 1322.0 ± NA3.0 ± 1.411.0 ± NA—
Week 1442.0 ± NA2.5 ± 0.711.0 ± NA—
Week 1562.0 ± NA3.0 ± 1.411.0 ± NA—

Adverse events

Collected over Up to approximately 161 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
>0 - 5 mg0/15 (0%)5/15 (33.3%)13/15 (86.7%)
>5 - 10 mg0/66 (0%)8/66 (12.1%)43/66 (65.2%)
>10 - 15 mg0/54 (0%)4/54 (7.4%)26/54 (48.1%)
>15 - 20 mg2/44 (4.5%)9/44 (20.5%)31/44 (70.5%)
>20 mg0/9 (0%)1/9 (11.1%)5/9 (55.6%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
Event>0 - 5 mg>5 - 10 mg>10 - 15 mg>15 - 20 mg>20 mg
PneumoniaInfections and infestations1/151/660/541/441/9
LeukocytosisBlood and lymphatic system disorders1/150/660/540/440/9
ThrombocytopeniaBlood and lymphatic system disorders1/150/660/540/440/9
Atrial fibrillationCardiac disorders1/150/660/540/440/9
Cardiac failure congestiveCardiac disorders1/150/660/540/440/9
Abdominal painGastrointestinal disorders1/150/661/541/440/9
NauseaGastrointestinal disorders1/150/660/540/440/9
VomitingGastrointestinal disorders1/150/660/540/440/9
DizzinessNervous system disorders1/151/660/540/440/9
HypoxiaRespiratory, thoracic and mediastinal disorders1/150/660/540/440/9
Most frequent other events
Showing 10 of 78
Most frequent other events
Event>0 - 5 mg>5 - 10 mg>10 - 15 mg>15 - 20 mg>20 mg
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders0/151/660/540/442/9
Night sweatsSkin and subcutaneous tissue disorders0/154/660/542/442/9
AnaemiaBlood and lymphatic system disorders3/157/664/545/440/9
ThrombocytopeniaBlood and lymphatic system disorders3/1511/664/542/441/9
Oedema peripheralGeneral disorders1/159/664/546/440/9
Upper respiratory tract infectionInfections and infestations1/153/662/546/441/9
Abdominal painGastrointestinal disorders2/154/662/542/441/9
NauseaGastrointestinal disorders2/156/662/544/440/9
VomitingGastrointestinal disorders2/153/660/543/440/9
FatigueGeneral disorders2/157/665/543/441/9

Baseline characteristics

Safety evaluable population included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Ruxolitinib 5 mg
Mean68.7 ± 9.44
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 5 mg
Female27
Male39
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 5 mg
Ethnicity — Hispanic or Latino3
Ethnicity — Non-Hispanic or Non-Latino63
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 5 mg
Race — White58
Race — Black or African American4
Race — Asian2
Race — Native Hawaiian or Pacific Islander1
Race — Other1
08

Study locations

38 sites
  • Birmingham, Alabama, United States
  • Beverly Hills, California, United States
  • Burbank, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Pomona, California, United States
  • San Diego, California, United States
  • New Haven, Connecticut, United States
  • Fort Myers, Florida, United States
  • Jacksonville, Florida, United States
  • Orange City, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Southfield, Michigan, United States
  • Saint Louis, Missouri, United States
  • Hackensack, New Jersey, United States
  • Morristown, New Jersey, United States
  • Somerville, New Jersey, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Hickory, North Carolina, United States
  • Canton, Ohio, United States
  • Cleveland, Ohio, United States
  • Portland, Oregon, United States
  • Danville, Pennsylvania, United States
  • Hershey, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
09

References and documents

Publications

  • Talpaz M, Prchal J, Afrin L, Arcasoy M, Hamburg S, Clark J, Kornacki D, Colucci P, Verstovsek S. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 x 109/L): Final Analysis of an Open-Label Phase 2 Study. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):336-346. doi: 10.1016/j.clml.2021.10.016. Epub 2021 Nov 2. PubMed 34911667 ↗
  • Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29;6(1):81. doi: 10.1186/1756-8722-6-81. PubMed 24283202 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Dec 2018, 90 months.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

Of 87 phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 111. This study's 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2011
First posted
May 5, 2011
StartActual
Jun 15, 2011
Primary completionActual
Dec 19, 2018
CompletionActual
Dec 19, 2018
Results first posted
Jan 28, 2020
Last update
Jan 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01348490
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 5, 2011
Start date
Jun 15, 2011
Primary completion
Dec 19, 2018
Completion
Dec 19, 2018
Results posted
Jan 28, 2020
Last update
Jan 28, 2020

Study contacts

Peter Langmuir, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion